FR22C1062I1 - DOSE ESCALATION ENZY REPLACEMENT THERAPY FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY - Google Patents

DOSE ESCALATION ENZY REPLACEMENT THERAPY FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY

Info

Publication number
FR22C1062I1
FR22C1062I1 FR22C1062C FR22C1062C FR22C1062I1 FR 22C1062 I1 FR22C1062 I1 FR 22C1062I1 FR 22C1062 C FR22C1062 C FR 22C1062C FR 22C1062 C FR22C1062 C FR 22C1062C FR 22C1062 I1 FR22C1062 I1 FR 22C1062I1
Authority
FR
France
Prior art keywords
enzy
treatment
replacement therapy
dose escalation
acid sphingomyelinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1062C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Icahn School of Medicine at Mount Sinai
Original Assignee
Genzyme Corp
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1062(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Icahn School of Medicine at Mount Sinai filed Critical Genzyme Corp
Publication of FR22C1062I1 publication Critical patent/FR22C1062I1/en
Application granted granted Critical
Publication of FR22C1062I2 publication Critical patent/FR22C1062I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
FR22C1062C 2009-08-28 2022-12-15 DOSE Escalation ENZYME REPLACEMENT THERAPY FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY Active FR22C1062I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28
EP10812683.0A EP2470199B1 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
PCT/US2010/047057 WO2011025996A2 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

Publications (2)

Publication Number Publication Date
FR22C1062I1 true FR22C1062I1 (en) 2023-02-03
FR22C1062I2 FR22C1062I2 (en) 2023-12-29

Family

ID=43625265

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1062C Active FR22C1062I2 (en) 2009-08-28 2022-12-15 DOSE Escalation ENZYME REPLACEMENT THERAPY FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY

Country Status (26)

Country Link
US (9) US8349319B2 (en)
EP (3) EP3998078A1 (en)
JP (7) JP5955219B2 (en)
KR (5) KR102094253B1 (en)
CN (3) CN105999238A (en)
AU (5) AU2010286550B2 (en)
BR (1) BR112012004377A2 (en)
CA (1) CA2773133A1 (en)
CL (1) CL2012000495A1 (en)
CY (1) CY1122128T1 (en)
DK (2) DK2470199T3 (en)
ES (2) ES2902229T3 (en)
FR (1) FR22C1062I2 (en)
HR (2) HRP20211992T1 (en)
HU (3) HUE057440T2 (en)
IL (3) IL300625A (en)
LT (2) LT2470199T (en)
MX (1) MX356873B (en)
NL (1) NL301211I2 (en)
PL (2) PL3482767T3 (en)
PT (2) PT3482767T (en)
RU (3) RU2569744C2 (en)
SI (2) SI2470199T1 (en)
TR (1) TR201911293T4 (en)
WO (1) WO2011025996A2 (en)
ZA (2) ZA201201435B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
WO2008154198A1 (en) 2007-06-06 2008-12-18 Genzyme Corporation Gene therapy for lysosomal storage diseases
PT3482767T (en) * 2009-08-28 2021-12-29 Icahn School Med Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US8882701B2 (en) * 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
WO2011146143A2 (en) 2010-05-21 2011-11-24 Ohmx Corporation Detection of cancer by assaying psa enzymatic activity
EP2685986B1 (en) 2011-03-18 2019-11-27 Genzyme Corporation Glucosylceramide synthase inhibitor
SI2753346T1 (en) 2011-09-07 2020-09-30 Mount Sinai School Of Medicine Ceramidase and cell differentiation
US9910033B2 (en) 2011-11-15 2018-03-06 Centogene Ag Method for the diagnosis of Niemann-Pick disease
ES2897825T3 (en) 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Ceramide levels in the treatment and prevention of infections
JOP20130273B1 (en) 2012-09-11 2021-08-17 Genzyme Corp Glucosylceramide synthase inhibitors
PT2968479T (en) 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
JO3713B1 (en) 2013-03-15 2021-01-31 Genzyme Corp SALT FORMS OF (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
TR201906195T4 (en) * 2013-05-14 2019-05-21 Centogene Ag Method for diagnosing Niemann pick disease.
RS59677B1 (en) * 2013-06-07 2020-01-31 Genzyme Corp Marker for acid sphingomyelinase disorders and uses thereof
JP6984854B2 (en) * 2015-10-08 2021-12-22 国立大学法人千葉大学 Pharmaceutical composition for preventing or treating Niemann-Pick disease type C
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
EP3672622B1 (en) * 2017-08-24 2023-11-08 Genzyme Corporation Recombinant human acid sphingomyelinase for use in treating abnormal bone conditions in acid sphingomyelinase deficiency patients
PE20210347A1 (en) 2017-10-02 2021-02-25 Denali Therapeutics Inc FUSION PROTEINS INCLUDING ENZYMES FROM ENZYME REPLACEMENT THERAPY
UY38238A (en) 2018-05-25 2019-12-31 Genzyme Corp PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY
JP2023534322A (en) 2020-07-24 2023-08-09 ジェンザイム・コーポレーション Pharmaceutical composition containing benglustat

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
DE69637875D1 (en) 1995-09-14 2009-04-30 Virginia Tech Intell Prop Production of lysosomal enzymes in plant expression systems
JP2820106B2 (en) 1996-02-29 1998-11-05 日本電気株式会社 Traffic shaper device
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
MXPA01006491A (en) 1998-12-23 2003-06-06 Thompson Boyce Plant Res Expression of immunogenic hepatitis b surface antigens in transgenic plants.
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
AU2001250856A1 (en) 2000-03-17 2001-10-03 Charles Arntzen Expression of recombinant human acetylcholinesterase in transgenic plants
AU2001269923A1 (en) * 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU2001286636A1 (en) 2000-08-25 2002-03-13 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
ATE384736T1 (en) 2001-04-30 2008-02-15 Zystor Therapeutics Inc SUB-CELLULAR TARGETING OF THERAPEUTIC PROTEINS
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
IES20011101A2 (en) * 2001-12-21 2003-06-25 Japkinstill Services Ltd A Bi-directional Messaging System
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
CN101027388A (en) * 2003-06-12 2007-08-29 建新公司 Modified human acid sphingomyelinase having increased activity, and methods for making the same
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CA2546863A1 (en) 2003-11-25 2005-06-09 Mount Sinai School Of Medicine Of New York University Chaperone-based therapy for niemann-pick disease
KR20070085291A (en) 2004-10-13 2007-08-27 프로탈릭스 리미티드 System and method for production of antibodies in plant cell culture
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
WO2007078806A2 (en) 2005-12-15 2007-07-12 The Research Foundation Of State University Of New York Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
AR059089A1 (en) * 2006-01-20 2008-03-12 Genzyme Corp INTRAVENTRICULAR ADMINISTRATION OF AN ENZYME FOR LISOSOMAL STORAGE DISEASES
EP1981546B1 (en) 2006-02-06 2014-06-04 The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center Enzyme replacement therapy for treating lysosomal storage diseases
CA3168881A1 (en) 2006-02-09 2007-08-23 Genzyme Corporation Slow intraventricular delivery
KR20080106433A (en) 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 Influenza antigens, vaccine compositions, and related methods
JP5302189B2 (en) 2007-04-27 2013-10-02 長瀬産業株式会社 Sphingomyelinase
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
BRPI0923047B8 (en) 2008-12-16 2021-05-25 Genzyme Corp methods for preparing protein-oligosaccharide conjugates
PT3482767T (en) * 2009-08-28 2021-12-29 Icahn School Med Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
EP2721151B1 (en) * 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders

Also Published As

Publication number Publication date
PT2470199T (en) 2019-08-07
AU2016216625A1 (en) 2016-09-15
US8658162B2 (en) 2014-02-25
NL301211I1 (en) 2022-12-28
JP2020090513A (en) 2020-06-11
RU2020128994A (en) 2022-03-02
JP7395693B2 (en) 2023-12-11
IL218324B (en) 2019-05-30
KR20210107153A (en) 2021-08-31
RU2731616C2 (en) 2020-09-07
KR20200034828A (en) 2020-03-31
FR22C1062I2 (en) 2023-12-29
HUE046598T2 (en) 2020-03-30
JP2013502933A (en) 2013-01-31
US20220305091A1 (en) 2022-09-29
DK3482767T3 (en) 2021-12-20
WO2011025996A3 (en) 2012-03-15
SI3482767T1 (en) 2022-03-31
US20160120957A1 (en) 2016-05-05
JP2016153408A (en) 2016-08-25
EP2470199A2 (en) 2012-07-04
US8709408B2 (en) 2014-04-29
ZA201201435B (en) 2020-05-27
WO2011025996A2 (en) 2011-03-03
JP5955219B2 (en) 2016-07-20
AU2018204156B2 (en) 2020-07-16
DK2470199T3 (en) 2019-08-05
MX356873B (en) 2018-06-18
JP2024026214A (en) 2024-02-28
KR20220104271A (en) 2022-07-26
PT3482767T (en) 2021-12-29
US20140335070A1 (en) 2014-11-13
RU2015145255A3 (en) 2019-08-12
IL300625A (en) 2023-04-01
CY1122128T1 (en) 2020-11-25
US20130078231A1 (en) 2013-03-28
JP6251307B2 (en) 2017-12-20
KR20230164773A (en) 2023-12-04
WO2011025996A9 (en) 2011-08-25
US20210077593A1 (en) 2021-03-18
US20130078230A1 (en) 2013-03-28
PL2470199T3 (en) 2019-11-29
KR102608546B1 (en) 2023-12-04
AU2010286550A1 (en) 2012-03-15
ZA201601362B (en) 2017-05-31
AU2010286550B2 (en) 2016-05-19
BR112012004377A2 (en) 2017-12-12
CA2773133A1 (en) 2011-03-03
IL266915A (en) 2019-07-31
KR102608551B1 (en) 2023-12-04
JP6952810B2 (en) 2021-10-20
AU2016216625B2 (en) 2018-07-05
CN106047835A (en) 2016-10-26
EP2470199B1 (en) 2019-05-22
CN102596232A (en) 2012-07-18
CL2012000495A1 (en) 2014-02-07
LT2470199T (en) 2019-10-10
ES2738859T3 (en) 2020-01-27
SI2470199T1 (en) 2019-11-29
US20190151419A1 (en) 2019-05-23
IL266915B2 (en) 2023-07-01
US8349319B2 (en) 2013-01-08
IL218324A0 (en) 2012-04-30
EP3482767B1 (en) 2021-10-06
EP3482767A1 (en) 2019-05-15
NL301211I2 (en) 2023-02-02
US9114139B2 (en) 2015-08-25
JP2023012499A (en) 2023-01-25
MX2012002449A (en) 2012-03-14
US20110052559A1 (en) 2011-03-03
HRP20211992T1 (en) 2022-04-01
RU2015145255A (en) 2019-01-11
RU2012111823A (en) 2013-10-10
US10188705B2 (en) 2019-01-29
HUE057440T2 (en) 2022-05-28
KR20120081077A (en) 2012-07-18
JP7167281B2 (en) 2022-11-08
CN105999238A (en) 2016-10-12
HRP20191385T1 (en) 2019-11-01
JP2018076322A (en) 2018-05-17
IL266915B1 (en) 2023-03-01
AU2020256322A1 (en) 2020-11-12
EP3998078A1 (en) 2022-05-18
US9655954B2 (en) 2017-05-23
AU2024201085A1 (en) 2024-03-07
LT3482767T (en) 2022-01-10
JP2022003065A (en) 2022-01-11
RU2569744C2 (en) 2015-11-27
PL3482767T3 (en) 2022-02-14
HUS2200050I1 (en) 2022-12-28
AU2018204156A1 (en) 2018-06-28
AU2020256322B2 (en) 2024-02-29
TR201911293T4 (en) 2019-08-21
KR102094253B1 (en) 2020-03-31
EP2470199A4 (en) 2013-03-27
ES2902229T3 (en) 2022-03-25
US20180055916A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
FR22C1062I1 (en) DOSE ESCALATION ENZY REPLACEMENT THERAPY FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
MX2020004099A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same.
ZA201208535B (en) Formulations of quinones for the treatment of ophthalmic diseases
IN2012DN06720A (en)
HK1186671A1 (en) Formulations for the treatment of disorders of the upper respiratory tract
EP2776059A4 (en) Pharmaceutical compositions containing proteases and methods for the treatment of lysosomal storage diseases
FR20C1026I1 (en) CICLESONIDE FOR THE TREATMENT OF DISEASES OF THE RESPIRATORY TRACT IN HORSES
FR2948687B1 (en) USE OF MICROARN FOR THE TREATMENT OF CHRONIC RESPIRATORY DISEASES
IL260078B (en) Therapy for use for the treatment of gaucher's disease
EP2306824A4 (en) Iontophoretic delivery of curcumin and curcumin analogs for the treatment of alzheimer's disease
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
IL232384A (en) Use of the compounds halofenate or halofenic acid for the preparation of medicaments for treatment of gout
EP2398789A4 (en) Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
SMT201600479B (en) NEW THERAPEUTIC SOLUTIONS FOR THE TREATMENT OF NEURO INFLAMMATORY CONDITIONS
BR112013020195A2 (en) citrate free pharmaceutical compositions comprising anakinra
FR2953723B1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ORTHOPEDIC DISEASES
FR2981060B1 (en) PROCESS FOR THE VALORISATION OF THE EFFLUENTS OF CHLOROFLUORHYDRIC ACID
IT1404270B1 (en) POSITIVE ALLGLASS MODULATORS OF MGLUR5 FOR USE AS MEDICATION IN THE THERAPEUTIC TREATMENT OF THE PHELAN-MCDERMID SYNDROME
SI2344166T1 (en) Pharmaceutical composition for the treatment of gastrointestinal irritation disorders
FR2976807B1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DEPENDENCE IN HUMAN BEINGS
FR2953412B1 (en) MEDICAMENT FOR THE TREATMENT OF GASTROINTESTINAL ULCERS
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
IL219050A0 (en) Pharmaceutical composition for the treatment of bladder disorders